Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults

Abstract

We conducted a preliminary open trial (trial 1) and a double-blind, placebo-controlled, crossover trial (trial 2) to examine how fermented milk containing the probiotic Bifidobacterium bifidum YIT 10347 affects gastric and lower abdominal symptoms in adults taking no medication. In trial 1, subjects with or without gastric and lower abdominal symptoms ingested fermented milk containing B. bifidum YIT 10347 daily for 2 wk. In trial 2, subjects with gastric symptoms ingested fermented milk containing B. bifidum YIT 10347 (active preparation) or placebo daily for 2 wk, followed by crossover for 3 wk after a washout period. Before (baseline) and 1 and 2 wk after ingestion, subjects completed a questionnaire. In trial 1 (305 subjects), the prevalence of gastric and lower abdominal symptoms was 46 and 58%, respectively, at baseline. Ingestion of B. bifidum YIT 10347 significantly decreased the prevalence of gastric and lower abdominal symptoms from 45 to 33% at 1 wk and to 28% at 2 wk, and from 57 to 40% at 2 wk, respectively. In subjects with gastric symptoms at baseline, the average gastric symptom score per subject significantly decreased by 0.9 at 1 wk and 1.2 at 2 wk. In trial 2 (27 subjects), ingestion of the active preparation significantly decreased the average gastric symptoms score per subject by 1.0 at 1 wk and 1.1 at 2 wk, but ingestion of placebo milk had no effect. No side effects were reported by any subjects in either trial. We conclude that fermented milk containing B. bifidum YIT 10347 has the potential to provide health benefits by alleviating gastric symptoms in subjects taking no medication.

Gastroesophageal Reflux Disease and Probiotics: A Systematic Review

“…In the analysis, 12 articles were included. One of the articles reported two interventions [25], and one article reported two probiotic study arms and one shared placebo arm [26]. Thus, the analysis ultimately included 14 comparisons.…”

“…Trends for improvement were observed by [31] with the modified GSRS and by [21] with the original GSRS, but not with the FSSG questionnaire. Five comparisons reported no improvement: [25] Studies A and B and [21,30,32]. The remaining comparisons did not assess or report reflux syndrome symptoms.…”

“…Three comparisons reported benefits for regurgitation, using frequency score as the endpoint, in which two single-strain probiotics were used: B. bifidum YIT 10347 in Study A in [25] and B. lactis HN019 for two comparisons in [26]. Gomi et al (2015) in Study A reported a lower frequency of regurgitation.…”

“…Three comparisons reported benefits for regurgitation, using frequency score as the endpoint, in which two single-strain probiotics were used: B. bifidum YIT 10347 in Study A in [25] and B. lactis HN019 for two comparisons in [26]. Gomi et al (2015) in Study A reported a lower frequency of regurgitation. Waller et al (2011) observed similar efficacy in reducing the frequency score for regurgitation at a high dose (17.2 × 10 9 CFU) by 12.6, and by 9.0 at the lower dose (1.8 × 10 9 CFU) [30].…”

The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study

“…This suggests that H. pylori infection is just one of the factors causing FD symptoms, and we believe it is important to clinically evaluate whether probiotics are effective against H. pylori -uninfected FD individuals. In addition, only a few reports have suggested thus far that probiotics might be effective for FD [15,16,17,18]. Therefore, we performed a double-blind, parallel-group, placebo-controlled, randomized, controlled trial (RCT) with L. gasseri OLL2716 in H. pylori -uninfected FD individuals.…”